Payment overview · 2025
General Payments
$126.09
1 reported records · 1 companies
Healthcare provider profile · identity verified
James M Williams, MD
Allopathic & Osteopathic Physicians|Family Medicine · GREEN BAY, WI · NPI 1407849433
Verified facts
What the public records show
CMS Open Payments records show James M Williams, MD received $126.09 in general payments during 2025 across 1 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $126.09 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $126.09 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $126.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 833 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 815 | 101 |
| Furosemide | Furosemide | 670 | 98 |
| Quetiapine Fumarate | Quetiapine Fumarate | 614 | 101 |
| Memantine Hcl | Memantine Hcl | 601 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 575 | 81 |
| Lisinopril | Lisinopril | 569 | 73 |
| Paroxetine Hcl | Paroxetine Hcl | 531 | 78 |
| Donepezil Hcl | Donepezil Hcl | 515 | 81 |
| Sertraline Hcl | Sertraline Hcl | 512 | 72 |
| Gabapentin | Gabapentin | 487 | 64 |
| Potassium Chloride | Potassium Chloride | 459 | 62 |
| Omeprazole | Omeprazole | 428 | 60 |
| Eliquis | Apixaban | 415 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 413 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 395 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 365 | 59 |
| Famotidine | Famotidine | 361 | 51 |
| Losartan Potassium | Losartan Potassium | 353 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 351 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 319 | 51 |
| Metformin Hcl | Metformin Hcl | 311 | 45 |
| Trazodone Hcl | Trazodone Hcl | 249 | 33 |
| Carvedilol | Carvedilol | 239 | 30 |
| Warfarin Sodium | Warfarin Sodium | 224 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 217 | 33 |
| Rivastigmine | Rivastigmine | 203 | 34 |
| Simvastatin | Simvastatin | 202 | 30 |
| Divalproex Sodium | Divalproex Sodium | 162 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 160 | 25 |
| Aripiprazole | Aripiprazole | 149 | 21 |
| Lamotrigine | Lamotrigine | 147 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 146 | 22 |
| Nystatin | Nystatin | 141 | 54 |
| Fluoxetine Hcl | Fluoxetine Hcl | 139 | 19 |
| Finasteride | Finasteride | 134 | 19 |
| Latanoprost | Latanoprost | 134 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 38 |
| Xarelto | Rivaroxaban | 124 | 16 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 122 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 121 | 36 |
| Benztropine Mesylate | Benztropine Mesylate | 116 | 16 |
| Rivastigmine | Rivastigmine Tartrate | 116 | 15 |
| Spironolactone | Spironolactone | 115 | 20 |
| Baclofen | Baclofen | 114 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 19 |
| Levetiracetam | Levetiracetam | 108 | 19 |
| Mirtazapine | Mirtazapine | 106 | 18 |
| Loperamide | Loperamide Hcl | 105 | 78 |
| Risperidone | Risperidone | 104 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 100 | 20 |
| Olanzapine | Olanzapine | 99 | 14 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 97 | 97 |
| Acetazolamide | Acetazolamide | 96 | 13 |
| Metformin Hcl Er | Metformin Hcl | 93 | 11 |
| Allopurinol | Allopurinol | 92 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 89 | 19 |
| Buspirone Hcl | Buspirone Hcl | 85 | 18 |
| Prednisone | Prednisone | 85 | 13 |
| Montelukast Sodium | Montelukast Sodium | 83 | 11 |
| Lorazepam | Lorazepam | 82 | 31 |
| Bupropion Xl | Bupropion Hcl | 81 | 13 |
| Jardiance | Empagliflozin | 80 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 79 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 38 |
| Tramadol Hcl | Tramadol Hcl | 75 | 24 |
| Atenolol | Atenolol | 71 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | suppressed |
| Myrbetriq | Mirabegron | 66 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 58 | suppressed |
| Ezetimibe | Ezetimibe | 58 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 58 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 57 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 56 | suppressed |
| Rexulti | Brexpiprazole | 56 | suppressed |
| Clonidine | Clonidine | 54 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 52 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 52 | suppressed |
| Topiramate | Topiramate | 52 | suppressed |
| Glipizide | Glipizide | 51 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 51 | 25 |
| Terazosin Hcl | Terazosin Hcl | 51 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 49 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 48 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 48 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | suppressed |
| Nyamyc | Nystatin | 47 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 30 |
| Lovastatin | Lovastatin | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 40 | 17 |
| Nystop | Nystatin | 39 | 21 |
| Bumetanide | Bumetanide | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 30 |
| Tamoxifen Citrate | Tamoxifen Citrate | 37 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Lidocaine | Lidocaine | 35 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 33 | 33 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Ketoconazole | Ketoconazole | 32 | 18 |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Ulticare Safety Pen Needle | Pen Needle, Diabetic, Safety | 31 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 30 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 12 |
| Anastrozole | Anastrozole | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | suppressed |
| Constulose | Lactulose | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Erythromycin | Erythromycin Base | 28 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 27 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Meloxicam | Meloxicam | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 15 |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 20 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Mesalamine | Mesalamine | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Budesonide Dr | Budesonide | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | 11 |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 11 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 11 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $126.09 · 1 records | Otsuka America Pharmaceutical, Inc. | REXULTI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error